Watchlist For Next Week 

Neumora Therapeutics Inc. - NMRA

ProKidney Corp. - PROK

Fate Therapeutics, Inc. - FATE

Generation Bio Co - GBIO

Aligos Therapeutics Inc. ALGS

Tenaya Therapeutics Inc. - TNYA

ParaZero Technologies Ltd. - PRZO

Gorilla Technology Group Inc. - GRRR

$BURU on high alert next week

 Why I Think BURU Could Explode Very Soon

Massive Upside Potential From a 52-Week Low Setup

Every once in a while, a micro-cap stock comes along that quietly builds up energy below the surface—until it erupts. You saw it last week in names like NITO, KTTA, ASST, KXIN, and I believe Nuburu, Inc. is similar to those stocks, and it may be on the verge of a major breakout.

Let me walk you through why I’m watching BURU closely right now.

1. Bottomed-Out Price, Powerful Technical Setup

At $0.14, BURU is trading just above its 52-week low of $0.133. While many traders avoid low-priced stocks near their lows, this is often where big reversals are born—and the chart is showing signs of strength beneath the surface:

 • RSI at 40 – Curling up, approaching of buy land

 • MACD Positive – potential bullish crossover

 • OBV Holding steady – showing accumulation, not distribution

 • Support holding at $0.13

 • 86% upside to next resistance around $0.25

This is what a coiled spring looks like before launch

2. Strategic Turnaround & Emerging Narrative

Earlier this year, BURU looked like just another struggling micro-cap. But recent developments show a clear pivot toward strategic innovation:

 • Reorganized capital structure and eliminated debt tied to payables

 • Focused R&D on defense and industrial laser solutions

 • Announced a key AI partnership with NexGenAI to enhance laser tech

 • Building out a new high-tech facility to scale up production

These are not meaningless press releases—they represent a real shift in strategy toward growth and relevance.

3. The Numbers Tell a Story

Let’s be real: BURU isn’t a perfect balance-sheet story yet. But that’s what makes it explosive—not expensive.

 • Market Cap: ~$6.8M

 • Float: ~48.5M shares

 • Short Interest: ~1.18% (thin short squeeze potential)

 • Cash: $209K | Debt: $9.5M

 • Free Cash Flow: -$6.6M

What this tells me: BURU is undervalued, overlooked, and high-risk—but potentially high-reward if catalysts start landing.

4. Bottom Line: The Setup is There

We’re not dealing with a hype stock here. This is a technical swing trade with fundamental backing and a growing storyline around defense tech and AI.

With the price holding just above support and volume ticking higher, momentum could shift any day—possibly starting now.

Final Thought

If you’re hunting for the next big swing below $0.20…

If you like setups that the crowd hasn’t caught onto yet…

If you know how to play high-risk, high-reward…

Keep your eyes on BURU.

$ONCY Undervalued Bottom player with Huge Potential

 Oncolytics Biotech, Inc.

Oncolytics Biotech Inc. (NASDAQ: ONCY): A Game-Changer in Cancer Immunotherapy

In the rapidly advancing field of oncology, Oncolytics Biotech Inc. (NASDAQ: ONCY) has emerged as a trailblazer, leveraging cutting-edge immunotherapy to combat some of the most challenging cancers. With its flagship therapy, pelareorep, and a series of promising clinical developments, this biotech innovator is poised to redefine cancer treatment. Let’s dive into a detailed due diligence (DD) to uncover why ONCY is capturing the spotlight.

Company Overview

At its core, Oncolytics Biotech is a company dedicated to harnessing the immune system to fight cancer. Pelareorep, its lead candidate, is a first-in-class immunotherapy that works by selectively targeting cancer cells while sparing healthy ones. This groundbreaking therapy not only attacks tumors but also stimulates the body’s immune response to prevent recurrence.

Key Metrics at a Glance

 • Market Cap: $64.4 million

 • Stock Price: $0.836 (as of January 22, 2025)

 • Shares Outstanding: ~77.07 million

 • Cash Position: $19.6 million (as of Q3 2024)

 • Debt: Minimal, with no significant liabilities reported

Recent Developments and Catalysts

1. Breakthrough Clinical Data

 • BRACELET-1 Study Success: Oncolytics recently announced promising results from the BRACELET-1 trial for HR+/HER2- metastatic breast cancer. These findings pave the way for potential FDA accelerated approval pathways and underscore pelareorep’s transformative potential.

 • New Data in GI Cancers: Compelling efficacy and safety data for anal and pancreatic cancers were unveiled at the 2025 ASCO GI Symposium, solidifying pelareorep’s versatility across multiple cancer types.

2. Strategic Partnerships

Collaborations with world-class pharmaceutical companies and research organizations have strengthened Oncolytics’ pipeline. These alliances focus on exploring combination therapies, expanding pelareorep’s applications, and accelerating development timelines.

3. Future Catalysts to Watch

 • Upcoming regulatory milestones and potential fast-track designations for pelareorep.

 • Expanded clinical trials targeting additional cancer types.

 • New partnerships with leading pharma giants, boosting credibility and resources.

Financial Strength

Oncolytics boasts a strong financial position, with $19.6 million in cash as of Q3 2024, ensuring the funding needed to advance its clinical programs. The lack of significant debt is a testament to the company’s fiscal discipline and operational efficiency.

Insider Actions

Although specific insider transactions haven’t been disclosed recently, Oncolytics maintains a high level of transparency in its financial and operational reporting. This commitment to governance inspires confidence in its management and long-term strategy.

Why Oncolytics Biotech?

Oncolytics Biotech Inc. is not just another biotech company; it’s a leader in immunotherapy innovation. With a solid pipeline, groundbreaking clinical results, and strong financial footing, the company has positioned itself as a potential disruptor in the fight against cancer.

Investment Highlights:

 • Proven track record of delivering clinical milestones.

 • Low market cap offers significant upside potential.

 • Ongoing collaborations with industry leaders amplify growth opportunities.

Technical Analysis

- Bottom player

- Technical Indicators Displaying positive divergences!! Mometum is coming back

Conclusion:

If you’re searching for a high-potential biotech stock with the science, strategy, and vision to revolutionize cancer treatment, Oncolytics Biotech Inc. (ONCY) deserves a closer look. Its innovative approach to immunotherapy, coupled with promising trial results and strategic partnerships, sets the stage for a breakthrough year in 2025.

Stay ahead of the curve—Oncolytics Biotech could be the hidden gem your portfolio has been waiting for!

6 Mega Short Squeeze candidates for this week $BZFD $DJT $WNW $ASTS $FUBO $ATNM

 

BZFD ---> Breakout watch for a 70% upside movement

DJT ---> Trump Name!! Could go for $70.00

WNW ---> Buying Pressure is back!! Big oversold!! 170% upside potential for gap fill

ASTS ---> A solid Bull Flag has formed! Break up could coming soon.

FUBO currently trading within its support range. According to the chart, this is a strong demand. It has recently significant bullish momentum, and a break above $4.25 could propel

 it higher.

ATNM Nice Trend Line Break!! Over $1.44 could squeeze hard.

Are you ready to take your investment journey to the next level? Every day, I share exclusive opportunities with my members that are rooted in technical and fundamental analysis—ensuring you have the edge when it comes to market insights. Don’t miss out  the chance to be part of something bigger. Join us today and experience the benefits of a community that’s committed to staying ahead of the market.

Get started NOW

Is $TGL Poised to Become the Next SuperNova? Exploring the Potential of Treasure Global Inc

 

Treasure Global Inc (NASDAQ: TGL)

Treasure Global, a Malaysian solutions provider, is at the forefront of developing innovative technology platforms. The company has introduced two key technology solutions: ZCITY App, which is a distinctive digital ecosystem that revolutionizes and streamlines the e-payment process for users while offering them rewards; and TAZTE, a digital food and beverage management system that equips merchants with comprehensive management and automated tools to digitize their operations. Additionally, Treasure Global serves as the master franchiser for well-known restaurant chains in Southeast Asia, integrating them with the TAZTE solution. As of March 19, 2024, ZCITY has amassed over 2,695,549 registered users.

Driving Innovation and Growth: A Recap of Treasure Global's Recent Milestones

Business Highlights:

As of December 31, 2023, there are over 2.68 million registered users, with a significant 53% being paid users who have made three or more transactions in the quarter.

The company has signed various agreements and partnerships, including a memorandum of understanding with UCSI Hospital to promote stem cell healthcare tourism, and a contract to supply curry puffs to a leading convenience store chain.

A landmark event was the hosting of an artificial intelligence robot for TikTok Live Commerce, alongside the launch of the ZCITY Live Commerce solution on Meta Platforms.

In collaboration with AIO Synergy Solutions, the company is developing a data center dedicated to AI applications.

Success of ZCITY’s Premium Store:

Treasure Global Inc. has reported the triumph of ZCITY's Premium Store, marking substantial achievements since its inception. A standout figure is the sale of over 6,000 Bill Saver Bonanza Packs post-launch, underscoring the platform's capacity to boost transactions. By harnessing sophisticated AI tools, ZCITY has procured critical insights into consumer spending patterns, facilitating the creation of highly customized packages that cater to the unique needs of each user. The Premium Store has been instrumental to TGL's success, contributing to a 48% year-over-year surge in revenue for the second quarter of the fiscal year 2024. Additionally, the company's net loss shrank from US$2.0 million to US$1.2 million in the same period, indicative of the strategic efficacy of initiatives like the ZCITY Premium Store. Sam Teo, the CEO of Treasure Global, conveyed his excitement over the notable sales and revenue upswing brought about by the Premium Store, mirroring the firm's dedication to innovation. Committed to pioneering advancements and providing unmatched user experiences, Treasure Global plans to further refine its services and broaden its market presence.

Strategic Partnership between Treasure Global and Silica-AI:

Treasure Global and Silica-AI have entered into a strategic alliance to transform the AI and IoT sectors throughout Southeast Asia. This partnership is set to offer state-of-the-art solutions that meet the changing requirements of customers, improve operational efficiencies, and generate enduring benefits for both partners and stakeholders. Southeast Asian businesses stand to gain from tailored recommendations, intelligent inventory management, predictive maintenance, superior customer service, dynamic pricing, and customized marketing initiatives. Utilizing AI algorithms and IoT sensors, companies can deliver individualized experiences, streamline operations, and enhance profits. The collaboration between Treasure Global and Silica-AI represents a major leap in promoting AI-led innovation in the region, heralding a new epoch of technological progress and digital superiority.

ZCITY Securing a US$2 Million Marketing Contract:

Treasure Global's affiliate, ZCITY, has clinched a landmark US$2 million marketing deal with Satria Dunia Sdn Bhd. The agreement is designed to elevate the status of Korean beauty products using ZCITY's sophisticated AI Marketing Engine. This pivotal development marks a considerable achievement for Treasure Global as ZCITY broadens its influence and capabilities within the beauty sector. By harnessing state-of-the-art AI technology, Treasure Global seeks to enhance brand exposure and accelerate sales for Korean beauty products. The Malaysian beauty market offers promising prospects, especially as Korean beauty products have been increasingly popular in recent times. This partnership highlights Treasure Global's dedication to transforming the beauty industry with inventive marketing strategies and propelling revenue growth in the ever-evolving beauty landscape.

Treasure Global has announced its 2024 Annual General Meeting of Shareholders will be held on Tuesday, June 11.

Technical View:

Market Cap. 6.88M - Sales 53.59M - Insider Owner 58% - Inst. Owner 11% - Shares Outstanding 17.90M - Float Shares 0.55M - Short Float 2.61% - No Debt

TGL --> This stock, a relatively tiny name, caught the attention of investors and traders last week. Its price jumped 29.34% on strong bullish volume, breaching the downtrend line and the 20-day moving average. The stock recently underwent a Reverse Split and has less than 1 million shares in float, indicating high run potential. With momentum picking up and recent significant headlines, surpassing the $6.00 mark could send it soaring. Recall, it was priced at $43.00 last October. Considering the nano float and renewed momentum, this stock could be promising. It's one to watch.